AddLife AB (STU:1AD1) Research & Development: €5.2 Mil (TTM As of Mar. 2026)


STU:1AD1 AddLife AB STU:1AD1
85 GF Score
Price €15.31
GF Value €13.19
! 5 Warning Signs
View Full Analysis

What is AddLife AB Research & Development?

AddLife AB STU:1AD1 +0.66% 85 Research & Development is €5.2 Mil as of Mar. 2026. GuruFocus rates STU:1AD1 with a GF Score™ of 85/100 and a GF Value™ of €13.19. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. AddLife AB's Research & Development for the three months ended in Mar. 2026 was €1.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €5.2 Mil.

AddLife AB  (STU:1AD1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AddLife AB Research & Development Related Terms

AddLife AB Research & Development Historical Data

* Premium members only.

The historical data trend for AddLife AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AddLife AB Research & Development Chart

AddLife AB Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.31 7.37 14.93 6.61 5.24

AddLife AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.27 1.27 1.29 1.39
STU:1AD1
85GF Score
AddLife AB STU:1AD1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AddLife AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €5.2 Mil mean?
AddLife AB (STU:1AD1) has a Research & Development of €5.2 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on AddLife AB and its competitors.
Is AddLife AB's Research & Development too high?
AddLife AB's current Research & Development is €5.2 Mil. Overall, AddLife AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's Research & Development compare to ISRG and BDX?
AddLife AB's Research & Development of €5.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on AddLife AB and its competitors. AddLife AB's current Research & Development is €5.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (STU:1AD1) has a current Research & Development of €5.2 Mil. The stock's GF Value™ is €13.19, compared to a current price of €15.31 — trading 16.1% above its estimated fair value. The current Research & Development is €5.2 Mil. AddLife AB's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For AddLife AB (STU:1AD1), the current Research & Development is €5.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AddLife AB (STU:1AD1) Overvalued in 2026?

Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued. The current stock price of €15.31 is trading 16.1% above its estimated GF Value™ of €13.19.

Key valuation signals for STU:1AD1:

  • Research & Development: €5.2 Mil
  • GF Value™: €13.19 vs. price of €15.31 (16.1% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the STU:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AddLife AB Business Description

Address Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
85GF Score

Get the complete analysis for STU:1AD1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.31
Price
€13.19
GF Value